Brussels, Belgium—In a press release, UCB announced that it plans to accelerate its US transition to focus on the specialists and will exit the primary care market in the US effective March 1, 2010. The transition is part of the company's strategic plan to become a patient-centric global biopharmaceutical leader focused on immunology and neurology.

"Following the successful US launches of our core products Cimzia^® (certolizumab pegol) and Vimpat^® (lacosamide) and awaiting FDA approval for the US launch of Neupro^® (rotigotine transdermal patch), we are focusing the resources of the total US organization and strengthening the foundation for the company's focus on immunology and neurology. After the exit of the primary care market in most of Western Europe 18 months ago, UCB will now exit the US primary care market, and focus its resources on providing solutions to patients who suffer from severe diseases with Cimzia, Vimpat as well as prepare for Neupro," said Roch Doliveux, UCB's Chief Executive Officer.